Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Test the Anti-Inflammatory Properties of RPL554 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2013
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Verona Pharma
- 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 09 Sep 2013 Status changed from recruiting to completed.
- 10 Jul 2012 New trial record